Kallia Apazoglou, Séverine Farley, Victor Gorgievski, Raoul Belzeaux, Juan Pablo Lopez, Julien Grenier, El Chérif Ibrahim, Marie-Anne El Khoury, Yiu C Tse, Raphaele Mongredien, Alexandre Barbé, Carlos E A de Macedo, Wojciech Jaworski, Ariane Bochereau, Alejandro Orrico, Elsa Isingrini, Chloé Guinaudie, Lenka Mikasova, Franck Louis, Sophie Gautron, Laurent Groc, Charbel Massaad, Ferah Yildirim, Vincent Vialou, Sylvie Dumas, Fabio Marti, Naguib Mechawar, Elise Morice, Tak P Wong, Jocelyne Caboche, Gustavo Turecki, Bruno Giros, Eleni T Tzavara
Depression, a devastating psychiatric disorder, is a leading cause of disability worldwide. Current antidepressants address specific symptoms of the disease, but there is vast room for improvement 1 . In this respect, new compounds that act beyond classical antidepressants to target signal transduction pathways governing synaptic plasticity and cellular resilience are highly warranted2-4 . The extracellular signal-regulated kinase (ERK) pathway is implicated in mood regulation5-7 , but its pleiotropic functions and lack of target specificity prohibit optimal drug development...
May 2018: Nature Medicine